EUCTR2010-019361-28-IT进行中（未招募）不适用
A randomized, double-blind, Placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of brivaracetam in subjects (=16 to 80 years old) with Partial Onset Seizures - ND
SCHWARZ BIOSCIENCES, INC A member of UCB Group of Companies0 个研究点目标入组 900 人开始时间: 2011年2月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written informed consent form is signed and dated by the subject or by the parent(s) or legal representative. The consent form or a specific assent form, where required, will be signed and dated by minors. 2. Subject/legal representative is considered reliable and capable of adhering to the protocol (eg, able to understand and complete diaries), visit schedule, or medication intake according to the judgment of the Investigator. 3. Subjects (male or female) from 16 to 80 years, both inclusive. Subjects under 18 years may only be included where legally permitted and ethically accepted. 4. Subjects with a body weight =40kg. 5. Female subjects without childbearing potential (premenarcheal, postmenopausal for at least 2 years, bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible. Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method. Oral or depot contraceptive treatment with at least 30µg ethinylestradiol per intake [or 50µg ethinylestradiol per intake if associated with any strong enzyme inducer (eg carbamazepine, phenobarbital, primidone, phenytoin, oxcarbazepine, St. John’s Wort, rifampicin)], monogamous relationship with vasectomized partner, or double-barrier contraception are acceptable methods. The subject must understand the consequences and potential risks of inadequately protected sexual activity, be educated about and understand the proper use of contraceptive methods, and undertake to inform the Investigator of any potential change in status. Abstinence will be considered as an acceptable method of contraception if the Investigator can document that the subject agrees to be compliant. 6. Well-characterized focal epilepsy/epileptic syndrome according to the 1989 International League Against Epilepsy (ILAE) classification. 7. Presence of an EEG reading compatible with the clinical diagnosis of focal epilepsy within the last 5 years. 8. Presence of a brain MRI/computed tomography (CT) scan performed within the last 2 years. 9. Subjects having at least 8 Type I seizures [POS; focal seizures (according to the 1981 ILAE classification)] during the 8-week Baseline Period with at least 2 Type I seizures during each 4-week interval of the Baseline Period. UCB 27-September-2010 Protocol Summary Brivaracetam N01358 Confidential Page 9 of 19 10. Subjects having at least 2 partial onset seizures whether or not secondarily generalized per month during the 3 months preceding V1. 11. Subjects being uncontrolled while treated by 1 or 2 permitted concomitant AED(s). Vagal Nerve Stimulation (VNS) is allowed and will be counted as a concomitant AED. 12. Permitted concomitant AED(s) and VNS being stable and at optimal dosage for the subject from at least 1 month (3 months for phenobarbital, phenytoin, and primidone) before V1 and expected to be kept stable during the Baseline and Treatment Period. Benzodiazepine taken more than once a week (for any indication) will be considered as a concomitant AED.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subject previously randomized within this study or any other prior study with BRV.• Seizure type IA non motor as only seizure type. • Subject has participated in another study of an investigational medication.• Subject is currently treated with LEV.• Subject has taken LEV within 90 days prior to V1.• Subject has any medical or psychiatric condition that.• Subject has a known hypersensitivity to any components of the investigational medicinal product orcomparative drugs as stated in this protocol.• Subject not able to read and understand the informed consent form, assent form, or seizure diary cardinstructions.• Subject has obvious cognitive impairment or mental retardation • Subjects whose seizures could not be reliably.• Subject has history or presence of status epilepticus during the year preceding V1 or during Baseline.• Subject has history or presence of known psychogenic nonepileptic seizures.
- •Subject on felbamate with less than 18 months exposure before V1.• Subject currently on vigabatrin. Subject with history of vigabatrin use but either no visual fields examination report available including standard static (Humphrey or Octopus) or kinetic perimetry (Goldman) or results of these examinations are abnormal.• Subject taking any drug with possible central nervous system (CNS) • Subject taking any drug that may significantly influence the metabolism of BRV cytochrome P450. • Subject has history of cerebrovascular accident, • Subject is suffering from severe cardiovascular disease or peripheral vascular disease • Subject has presence of any sign (clinical or imaging techniques) suggesting rapidly progressing brain disorder or brain tumor.. • Subject has any clinical conditions (eg, bone marrow depression, chronic hepatic disease, and/or severe renal impairment). • Subject has presence of a terminal illness. • Subject has presence of a serious infection. • Subject has history of severe adverse hematologic reaction to any drug.• Subject is suffering from severe disturbance of hemostasis.• Subject has impaired hepatic function: ALT/SGPT, AST/SGOT, alkaline phosphatase of more than 2 times the upper limit of the reference range. • Gamma-glutamyltransferase (GGT) values of more than 3 times the upper limit of the reference range. parameters: creatinine clearance calculated <30mL/min, platelets <100,000/µL, or neutrophil cells <1,800/µL.
- •Subject has clinically significant ECG abnormalities according to the Investigator. • Subject has history of suicide attempt prior to randomization. • Subject has ongoing psychiatric disease other than mild controlled disorder. • Subject has known allergic reaction or intolerance to pyrrolidine derivatives and/or investigational product excipients. • Subject has known multiple drug allergies or severe drug allergy. • Subject is pregnant or lactating woman. • Subject has known alcohol or drug addiction or abuse within the last 2 years. • Investigators, co-Investigators, their spouses or children, or any study collaborators.
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of RO7123520 as Adjunct Treatment in Patients With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to TNF-a InhibitorsMedDRA version: 20.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2016-002126-36-ESF. Hoffmann-La Roche Ltd204
进行中（未招募）
1 期
Efficacy and safety study evaluating a new sublingual treatment in HDM allergic rhinitisHouse dust mite allergic rhinitisMedDRA version: 18.0Level: LLTClassification code 10001725Term: Allergic rhinitis due to other allergenSystem Organ Class: 100000004855EUCTR2014-004223-46-ESStallergenes S.A.990
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of Ritalin® LA in adult patients with childhood-onset ADHDAdult patients with childhood-onset Attention Deficit Hyperactivity DisorderMedDRA version: 12.1Level: LLTClassification code 10003735Term: Attention deficit-hyperactivity disorderMedDRA version: 12.1Level: LLTClassification code 10003736Term: Attention deficit/hyperactivity disorderMedDRA version: 12.1Level: LLTClassification code 10003737Term: Attention deficit/hyperactivity disorder NOSMedDRA version: 12.1Level: PTClassification code 10003736Term: Attention deficit/hyperactivity disorderEUCTR2010-021533-31-DKovartis Pharma Services AG700
进行中（未招募）
1 期
Safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyDiabetic nephropathyMedDRA version: 16.1 Level: PT Classification code 10061835 Term: Diabetic nephropathy System Organ Class: 10038359 - Renal and urinary disordersEUCTR2012-004179-38-NLBayer HealthCare AG823
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapyDiffuse Large B-Cell LymphomaMedDRA version: 19.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000498-40-ATovartis Pharma Services AG487